Stockscreener 앱 받기
2.34
1.68%
-0.04
시간 외 거래:
2.32
-0.02
-0.85%
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Signal strength of ImmunityBio Inc. stock in tech scannersJuly 2025 Fed Impact & Expert Approved Momentum Trade Ideas - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.July 2025 Macro Moves & AI Forecasted Stock Moves - Newser
What the charts say about ImmunityBio Inc. todayEarnings Beat & Stepwise Trade Signal Implementation - Newser
Using Python tools to backtest ImmunityBio Inc. strategiesRecession Risk & Technical Pattern Recognition Alerts - Newser
Volatility clustering patterns for ImmunityBio Inc.Volume Spike & Free Risk Controlled Daily Trade Plans - Newser
What ImmunityBio (IBRX)'s Early Glioblastoma Disease Control Results Could Mean for Shareholders - Yahoo Finance
Chart based analysis of ImmunityBio Inc. trends2025 Momentum Check & Smart Money Movement Tracker - Newser
Combining machine learning predictions for ImmunityBio Inc.Portfolio Return Summary & Verified Momentum Stock Ideas - Newser
ImmunityBio Reports Promising Early Results in Glioblastoma Trial with 100% Disease Control Rate - AInvest
Analyzing recovery setups for ImmunityBio Inc. investorsJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - Newser
Reversal indicators forming on ImmunityBio Inc. stock2025 Geopolitical Influence & Growth Focused Entry Reports - Newser
Comparing ImmunityBio Inc. in custom built stock radars2025 Price Targets & Safe Entry Zone Tips - Newser
Using data tools to time your ImmunityBio Inc. exitDollar Strength & Free Real-Time Market Sentiment Alerts - Newser
ImmunityBio: D. Boral Capital Maintains Buy Rating with Raised PT to $24 - AInvest
Analyzing ImmunityBio Inc. with multi timeframe chartsJuly 2025 Institutional & Risk Controlled Daily Plans - Newser
What technical models suggest about ImmunityBio Inc.’s comebackQuarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
ImmunityBio rises on data for NK cell therapy, device combo for glioblastoma - Seeking Alpha
ImmunityBio Inc. stock prediction for this weekQuarterly Earnings Report & Technical Confirmation Trade Alerts - Newser
ImmunityBio Inc. Facing Inflection Point in Trend Analysis getLinesFromResByArray error: size == 0 - newsyoung.net
ImmunityBio stock surges after promising glioblastoma treatment results By Investing.com - Investing.com Canada
ImmunityBio stock surges after promising glioblastoma treatment results - Investing.com
ImmunityBio reports promising results in glioblastoma treatment trial - Investing.com
ImmunityBio's ANKTIVA and Optune Gio: A Dual-Immunotherapy Breakthrough in Recurrent Glioblastoma and Long COVID - AInvest
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Yahoo Finance
Applying Wyckoff theory to ImmunityBio Inc. stockJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - Newser
Is now a turning point for ImmunityBio Inc.Inflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Will ImmunityBio Inc. benefit from macro trendsJuly 2025 Update & AI Powered Market Entry Strategies - Newser
Live market analysis of ImmunityBio Inc.2025 Market Overview & Growth Focused Investment Plans - Newser
Published on: 2025-08-23 23:59:47 - Newser
Developing predictive dashboards with ImmunityBio Inc. data2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser
Real time scanner hits for ImmunityBio Inc. explainedMarket Trend Summary & High Conviction Buy Zone Alerts - Newser
Is ImmunityBio Inc.’s growth already priced in2025 Macro Impact & Consistent Return Strategy Ideas - 더경남뉴스
Day 5 of Loss Streak for ImmunityBio Stock with -20% Return (vs. -12% YTD) [8/20/2025] - Trefis
How ImmunityBio Inc. stock reacts to Fed policy changesJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - Newser
Vir Biotechnology shares rise 2.52% premarket after ImmunityBio's new Phase 2 trial launch. - AInvest
ImmunityBio shares rise 3.07% premarket after announcing Phase 2 study of ANKTIVA® for long COVID. - AInvest
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: D. Boral Capital keeps Buy, raises PT to $24 from $24. - AInvest
Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent
ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener
ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com
ImmunityBio Inc. Stock Flags Risk Zone in Volatility IndexJuly 2025 EndofMonth & Entry Point Confirmation Signals - sundaytimes.kr
ImmunityBio Wins U.K. Approval - Los Angeles Business Journal
0.98%
8.06%
자본화:
|
볼륨(24시간):